Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pseudoephedrine for retrograde ejaculation after retroperitoneal lymph node dissection in testicular cancer
ACTRN12622000542796Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pseudoephedrine in retrograde ejaculation, sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Proportion achieving adequate total sperm count in antegrade ejaculate. Started Sep 2022; status: completed.
02
Drugs
pseudoephedrine
03
Conditions
retrograde ejaculation
Beyond the preview
Go deeper on ACTRN12622000542796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000542796.